Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CTX112

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by CRISPR Therapeutics

Phase 1/2 Most advanced trial
CRSP Developer
1 Registered trials

What is CTX112?

CTX112 (zugocabtagene geleucel) is an allogeneic CAR T-cell therapy made from human T lymphocytes engineered to express a chimeric antigen receptor specific for CD19 and gene-edited with CRISPR-Cas9 to remove endogenous TCR, TGFbRII and Regnase-1. It recognizes CD19-expressing tumor cells and kills them through cytotoxic T-lymphocyte activity. It is studied in B-cell lymphomas and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zugocabtagene geleucel, zugo-cel
Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Pathways
cytotoxic T-lymphocyte-mediated killing
Therapy area
Oncology
Developer
CRISPR Therapeutics (CRSP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05643742 Phase 1/2 B-cell Lymphoma Recruiting CRSP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell LymphomaB-cell MalignancyFollicular LymphomaLarge B-cell LymphomaMantle Cell LymphomaMarginal Zone LymphomaNon-Hodgkin Lymphoma

Other drugs acting on CD19

More from CRISPR Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.

Follow CRSP, the company behind CTX112

See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRSP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.